TD Cowen Maintains Buy on Iovance Biotherapeutics, Raises Price Target to $10

Benzinga Newsdesk www.benzinga.com Positive 72.8%

Neg 0% Neu 0% Pos 72.8%

TD Cowen analyst Nicholas Lorusso maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and raises the price target from $7 to $10.